Danish biopharmaceutical firm Zealand Pharma has announced that its partner Sanofi has submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe.

Lixisenatide, developed by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for type 2 diabetes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Sanofi is set to complete the Phase III development of the drug as a new treatment for the disease.

The marketing authorisation application includes data from the GetGoal Phase III programme, comprising nine studies involving over 4,300 patients.

The trial is intended to provide data for supporting lixisenatide as a treatment for type 2 diabetes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now